GET DAILY SIGNALSWhy Is Dentsply Sirona (XRAY) Stock Down -11.50% Today?
Key Takeaways
- Shares plunged 11.50% after XRAY reported third-quarter results that missed Wall Street estimates on both revenue and earnings.
- Primary catalyst: Management cut full-year 2026 adjusted EPS guidance to $1.20–$1.30 from $1.40–$1.50 and guided revenue toward the low end of its range.
- Secondary drivers: Broad weakness across dental segments, a zero free-cash-flow quarter, and a fresh round of analyst price-target cuts.
- Market context: The sell-off was company-specific, amplified by a cautious tape across equities on November 6.
- What to watch next: Whether the company's "Return-to-Growth" plan shows visible progress in the fourth quarter and fiscal 2027.
- For deeper detail on valuation and targets, explore Price Targets, Earnings, and Forecast pages.
- Discover AI-driven trading ideas for this and thousands of other tickers on the Trending AI Robots page.
Opening Summary
Dentsply Sirona Inc. (XRAY), one of the world's largest manufacturers of dental equipment, consumables, and technology, saw its stock fall sharply in Thursday's session. Shares traded down roughly 11.50%, sliding from a prior close of $10.09 to about $8.93. The decline extended an after-hours slide that began Wednesday night, after the company reported third-quarter results that missed consensus and issued a weaker full-year outlook. The move was driven overwhelmingly by company-specific fundamentals rather than broad macroeconomic tailwinds.
Earnings Miss Triggers the Sell-Off
The central catalyst was a disappointing third-quarter report. Revenue fell 7.5% year over year to $836 million, below the roughly $860 million analysts had expected. Adjusted earnings per share came in at $0.29, short of the $0.31 consensus. Weakness was broad-based across the company's dental businesses: Orthodontic and Implant Solutions revenue dropped 17%, Connected Technology Solutions fell 11%, and Essential Dental Solutions slipped 4%. Lower dental volumes, planned distributor inventory reductions, and the absence of Byte revenues all weighed on the top line.
Guidance Cut Compounds the Damage
Perhaps more damaging than the headline miss was the downward revision to full-year guidance. Management trimmed adjusted EPS guidance to a range of $1.20 to $1.30, down from $1.40 to $1.50, and pointed revenue toward the low end of its range at roughly $3.5 billion. The reduced outlook signals that the company's "Return-to-Growth" turnaround plan is taking longer to produce visible results than investors had hoped. A one-time, non-recurring $39 million inventory-related benefit also flattered the quarter's margins, raising questions about the underlying quality of the results.
Analyst Reactions and Sector Pressure
The earnings-driven move was reinforced by a fresh wave of analyst actions. Several firms trimmed price targets in the wake of the report, reflecting a consensus view that the turnaround faces a longer, more difficult path. The cash-flow picture added to the concern, with operating cash flow declining and free cash flow falling to zero for the quarter. Meanwhile, broader equity markets offered little support, keeping the pressure squarely on the stock's fundamentals.
Market Context and Trading Activity
Trading volume was elevated as investors digested the results, with the shares moving decisively lower from the open and approaching levels near the stock's 52-week low. The decline diverged from the performance of broader indices, underscoring that this was a company-specific move rather than a sector-wide rotation. The magnitude of the drop reflects a repricing of the stock as analysts and investors recalibrate expectations for the company's near-term recovery trajectory.
What Comes Next for XRAY
Looking ahead, investors will focus on whether XRAY can demonstrate tangible progress in its priority growth areas, including implants, endodontics, and its Wellspect Healthcare unit, which posted record quarterly revenue. Fourth-quarter results and any commentary on fiscal 2027 will be closely watched for signs that distributor destocking in Western Europe is easing and that newly expanded U.S. dealer networks are translating into sales momentum. Risks include persistent pricing pressure in EMEA, geopolitical uncertainty, and a slower-than-expected payoff from the company's commercial investments.
Trending AI Robots
Tickeron's Trending AI Robots page curates the strongest-performing AI trading bots under current market conditions from a broader universe of hundreds of bots covering thousands of tickers. These automated strategies vary by approach, timeframe, performance metrics, and the symbols they trade. Exploring the page can help traders identify systematic ideas aligned with today's fast-moving tape.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XRAY in upward trend: 10-day moving average moved above 50-day moving average on November 05, 2026
The 10-day moving average for XRAY crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XRAY as a result. In 57 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for XRAY just turned positive on October 09, 2026. Looking at past instances where XRAY's MACD turned positive, the stock continued to rise in 31 of 53 cases over the following month. The odds of a continued upward trend are 58%.
Following a +2.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where XRAY advanced for three days, in 172 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The 10-day RSI Indicator for XRAY moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 19 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 63 cases where XRAY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.
XRAY moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
XRAY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XRAY entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.396) is normal, around the industry mean (4.955). P/E Ratio (-3.465) is within average values for comparable stocks, (40.806). Projected Growth (PEG Ratio) (0.601) is also within normal values, averaging (4.143). XRAY's Dividend Yield (0.068) is considerably higher than the industry average of (0.005). P/S Ratio (0.557) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating fairly steady price growth. XRAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a global denal eqipment company
Industry PharmaceuticalsOther
Advertisement